Kimura Fuminori, Takahashi Kentaro, Takebayashi Koichi, Fujiwara Mutsuko, Kita Nobuyuki, Noda Yoichi, Harada Nobuhiro
Department of Obstetrics and Gynecology, Shiga University of Medical Science, Seta Tsukinowa-Cho, Otsu, Japan.
Fertil Steril. 2007 Jun;87(6):1468.e9-12. doi: 10.1016/j.fertnstert.2006.09.010. Epub 2007 Jan 12.
To assess the effect of aromatase inhibitors with GnRH agonist for a severe symptomatic adenomyosis that is refractory to GnRH agonist and danazol with GnRH agonist.
Case report.
Clinical practice in university hospital.
PATIENT(S): A 34-year-old woman with a complaint of severe dysmenorrheal, symptomatic anemia, and a desire to retain fertility.
INTERVENTION(S): Aromatase inhibitor anastrozole given orally (1.0 mg or 2.0 mg daily) for 16 weeks and GnRH agonist given monthly (injected SC, 1.8 mg) for 4 months.
MAIN OUTCOME MEASURE(S): Measurements of uterine volume and levels of serum E(2), estrone, A, dehydroepiandrosterone sulfate, LH, FSH, and CA125.
RESULT(S): Uterine volume was reduced. The reduction rate of uterine volume estimated by magnetic resonance imaging and ultrasonography was 60% after 8 weeks of treatment.
CONCLUSION(S): Aromatase inhibitor with GnRH agonist therapy was useful for the management of a severely adenomyotic woman whose desire was for conservative treatment.
评估芳香化酶抑制剂联合促性腺激素释放激素（GnRH）激动剂对GnRH激动剂及达那唑联合GnRH激动剂治疗无效的重度症状性子宫腺肌病的疗效。
病例报告。
大学医院临床实践。
一名34岁女性，主诉严重痛经、症状性贫血，并有保留生育能力的愿望。
口服芳香化酶抑制剂阿那曲唑（每日1.0毫克或2.0毫克），持续16周；每月注射GnRH激动剂（皮下注射，1.8毫克），持续4个月。
测量子宫体积以及血清雌二醇（E₂）、雌酮、雄烯二酮、硫酸脱氢表雄酮、促黄体生成素（LH）、促卵泡生成素（FSH）和CA125水平。
子宫体积减小。治疗8周后，磁共振成像和超声检查估计子宫体积缩小率为60%。
芳香化酶抑制剂联合GnRH激动剂治疗对希望接受保守治疗的重度子宫腺肌病女性有效。
